Together for
enhancing knowledge

Insights

Brochures

Snapshot of end-to-end safety services across the drug development lifecycle.

View All →

Videos

Perspectives by leadership team on drug safety, ensuring compliance and emerging therapies.

View All →

Case Studies

Learn more about how we delivered exceptional value to our customers across the product lifecycle.

View All →

Whitepapers/ Articles

Subject matter experts share their views on patient safety and emerging therapies.

View All →

Blogs

Point of view on the aspects of drug safety, regulations and organizational excellence.

View All →

Infographics

Visual representation of scientific and medical knowledge around drug safety and emerging therapies.

View All →

Webinar Recordings

View recording of webinars on drug safety and regulatory landscape.

View All →

COVID-19: Patients’ Safety First

Shot of a doctor talking to a patient in a wheelchair in a hospital corridor

The ongoing COVID-19 outbreak has affected millions of people globally. Governments, public health agencies, pharmaceutical companies, healthcare and research organizations are pursuing the common purpose to contain further spread and develop safe and effective treatment and preventive measures at the earliest.

Currently, there are no specific vaccines, biologics or drugs for prevention or treatment for COVID-19. Multiple therapeutic modalities including vaccines, immunomodulators and drugs are being investigated at a large scale for potential effectiveness against the virus. The pandemic paradigm requires multiple activities to be conducted at financial risk to developers and manufacturers and without knowing whether the vaccine candidate will be safe and effective. Effective benefit risk analysis of these therapies acts as a backbone to ensure fast track movement of the product across various stages from clinical trials to commercialization.

APCER Life Sciences is committed to the safety of its people and is prepared to support companies dedicated towards developing vaccines and treatments for this disease.

Testimonials

  • Medical Director
    APCER’s speed, responsiveness and flexibility to meet our safety needs is something we have always valued. APCER has helped harmonize our global pharmacovigilance operations and made us compliant with ever changing regulations.
    Medical Director
    US-based specialty pharmaceutical company
  • QPPV and Pharmacovigilance Head
    The audit was carried out professionally and objectively. The scope of the audit was relevant and appropriate, and time efficient. The discussions during the audit were constructive and recommendations where helpful and appropriate. The team members involved in the audit had a positive experience and were made to feel at ease by the auditors.
    QPPV and Pharmacovigilance Head
  • Senior Director
    We are thankful to team APCER for bringing in strong practices & helping inspection readiness in our pharmacovigilance framework which led to successful FDA audits.
    Senior Director
    US-based pharmaceutical company
  • Head, Clinical Trial Transparency
    APCER’s invaluable support with Clinical trial disclosure deadlines helped us in timely submissions of periodic reports.
    Head, Clinical Trial Transparency
    Top 10 pharmaceutical company with operations in the EU and US
  • AVP, Pharmacovigilance
    We appreciate APCER for its efficiency in responding to matters that they get even at the eleventh hour. Working with APCER has made compliance a lot easier.
    AVP, Pharmacovigilance
    US-based pharmaceutical company
  • Senior Director
    We are thankful to team APCER for bringing in strong practices & helping inspection readiness in our pharmacovigilance framework which led to successful FDA audits.
    Senior Director
    US-based pharmaceutical company

How can we work together for better health?

    By clicking Submit, you agree to our Privacy Policy and to be contacted at the email and/or phone number you provided.